Cover Image

Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies

Introduction: Thalidomide and its analogs [small molecule immunomodulatory drugs (IMiDs®)] are among the most successful new therapeutic agents of recent years. Thalidomide is now an integral part of multiple myeloma (MM) therapy. Lenalidomide has been approved for the treatment of patients with rel...

Full description

Saved in:
Bibliographic Details
Main Authors: Vallet, Sonia (Author) , Witzens-Harig, Mathias (Author) , Jäger, Dirk (Author) , Podar, Klaus (Author)
Format: Article (Journal)
Language:English
Published: 13 Feb 2012
In: Expert opinion on pharmacotherapy
Year: 2012, Volume: 13, Issue: 4, Pages: 473-494
ISSN:1744-7666
DOI:10.1517/14656566.2012.656091
Online Access:Verlag, Volltext: http://dx.doi.org/10.1517/14656566.2012.656091
Verlag, Volltext: https://doi.org/10.1517/14656566.2012.656091
Get full text
Author Notes:Sonia Vallet, Mathias Witzens-Harig, Dirk Jaeger, Klaus Podar

MARC

LEADER 00000caa a2200000 c 4500
001 1571770712
003 DE-627
005 20230426124233.0
007 cr uuu---uuuuu
008 180406s2012 xx |||||o 00| ||eng c
024 7 |a 10.1517/14656566.2012.656091  |2 doi 
035 |a (DE-627)1571770712 
035 |a (DE-576)501770712 
035 |a (DE-599)BSZ501770712 
035 |a (OCoLC)1341001675 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Vallet, Sonia  |d 1976-  |e VerfasserIn  |0 (DE-588)105867207X  |0 (DE-627)797396403  |0 (DE-576)414826493  |4 aut 
245 1 0 |a Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies  |c Sonia Vallet, Mathias Witzens-Harig, Dirk Jaeger, Klaus Podar 
264 1 |c 13 Feb 2012 
300 |a 22 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 06.04.2018 
520 |a Introduction: Thalidomide and its analogs [small molecule immunomodulatory drugs (IMiDs®)] are among the most successful new therapeutic agents of recent years. Thalidomide is now an integral part of multiple myeloma (MM) therapy. Lenalidomide has been approved for the treatment of patients with relapsed MM and 5q-myelodysplastic syndromes (MDS). Currently, more than 400 clinical trials are evaluating the activity of lenalidomide, alone or in combination with other conventional or novel therapies, in newly diagnosed MM and 5q-MDS. Based on their broad range of actions within the tumor microenvironment, IMiDs are currently also evaluated in a wide variety of additional hematologic and solid malignancies. Areas covered: This paper reviews the historic development of thalidomide and its derivatives and presents novel insights into their mode of action. Moreover, it discusses up-to-date clinical trials investigating IMiDs and potential future research and therapeutic perspectives in MM and other malignancies. Expert opinion: Although IMiDs have emerged as powerful agents for the treatment of hematologic and solid tumors, more preclinical and clinical studies are urgently needed both to increase our knowledge of their mechanisms of action, and to optimize their clinical use, in order to further improve the patient's quality of life and survival. 
650 4 |a angiogenesis 
650 4 |a birth defects 
650 4 |a cereblon 
650 4 |a immunomodulation 
650 4 |a lenalidomide 
650 4 |a multiple myeloma 
650 4 |a myelodysplastic syndromes 
650 4 |a pomalidomide 
650 4 |a thalidomide 
700 1 |a Witzens-Harig, Mathias  |e VerfasserIn  |0 (DE-588)1050736516  |0 (DE-627)784812322  |0 (DE-576)404988970  |4 aut 
700 1 |a Jäger, Dirk  |d 1964-  |e VerfasserIn  |0 (DE-588)1032507535  |0 (DE-627)738505323  |0 (DE-576)380074125  |4 aut 
700 1 |a Podar, Klaus  |e VerfasserIn  |0 (DE-588)1058672169  |0 (DE-627)797396594  |0 (DE-576)414826795  |4 aut 
773 0 8 |i Enthalten in  |t Expert opinion on pharmacotherapy  |d Abingdon, Oxon : Routledge, Taylor & Francis, 1999  |g 13(2012), 4, Seite 473-494  |h Online-Ressource  |w (DE-627)324741901  |w (DE-600)2030119-4  |w (DE-576)302969330  |x 1744-7666  |7 nnas  |a Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies 
773 1 8 |g volume:13  |g year:2012  |g number:4  |g pages:473-494  |g extent:22  |a Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies 
856 4 0 |u http://dx.doi.org/10.1517/14656566.2012.656091  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u https://doi.org/10.1517/14656566.2012.656091  |x Verlag  |3 Volltext 
951 |a AR 
992 |a 20180406 
993 |a Article 
994 |a 2012 
998 |g 1058672169  |a Podar, Klaus  |m 1058672169:Podar, Klaus  |d 910000  |e 910000PP1058672169  |k 0/910000/  |p 4  |y j 
998 |g 1032507535  |a Jäger, Dirk  |m 1032507535:Jäger, Dirk  |d 910000  |e 910000PJ1032507535  |k 0/910000/  |p 3 
998 |g 1050736516  |a Witzens-Harig, Mathias  |m 1050736516:Witzens-Harig, Mathias  |d 910000  |d 910100  |e 910000PW1050736516  |e 910100PW1050736516  |k 0/910000/  |k 1/910000/910100/  |p 2 
998 |g 105867207X  |a Vallet, Sonia  |m 105867207X:Vallet, Sonia  |d 910000  |e 910000PV105867207X  |k 0/910000/  |p 1  |x j 
999 |a KXP-PPN1571770712  |e 3005244776 
BIB |a Y 
SER |a journal 
JSO |a {"type":{"media":"Online-Ressource","bibl":"article-journal"},"title":[{"title":"Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies","title_sort":"Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies"}],"origin":[{"dateIssuedKey":"2012","dateIssuedDisp":"13 Feb 2012"}],"note":["Gesehen am 06.04.2018"],"id":{"eki":["1571770712"],"doi":["10.1517/14656566.2012.656091"]},"physDesc":[{"extent":"22 S."}],"name":{"displayForm":["Sonia Vallet, Mathias Witzens-Harig, Dirk Jaeger, Klaus Podar"]},"recId":"1571770712","relHost":[{"id":{"eki":["324741901"],"issn":["1744-7666"],"zdb":["2030119-4"]},"recId":"324741901","physDesc":[{"extent":"Online-Ressource"}],"disp":"Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignanciesExpert opinion on pharmacotherapy","type":{"media":"Online-Ressource","bibl":"periodical"},"pubHistory":["1.1999/2000 -"],"origin":[{"dateIssuedKey":"1999","publisher":"Routledge, Taylor & Francis ; Informa Healthcare","dateIssuedDisp":"1999-","publisherPlace":"Abingdon, Oxon ; London [u.a.]"}],"title":[{"subtitle":"EOP","title_sort":"Expert opinion on pharmacotherapy","title":"Expert opinion on pharmacotherapy"}],"part":{"volume":"13","extent":"22","pages":"473-494","year":"2012","issue":"4","text":"13(2012), 4, Seite 473-494"},"titleAlt":[{"title":"EOP"}],"language":["eng"]}],"person":[{"given":"Sonia","role":"aut","family":"Vallet","display":"Vallet, Sonia"},{"role":"aut","given":"Mathias","display":"Witzens-Harig, Mathias","family":"Witzens-Harig"},{"display":"Jäger, Dirk","family":"Jäger","given":"Dirk","role":"aut"},{"given":"Klaus","role":"aut","display":"Podar, Klaus","family":"Podar"}],"language":["eng"]} 
SRT |a VALLETSONIUPDATEONIM1320 

Similar Items